Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan migraine prior auth Coverage…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    Migraine Acute Treatment Agents Prior Authorization

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization requirements and quantity/daily dose limit requests for acute migraine treatments (triptans, gepants, ditans, ergot alkaloids, NSAIDs, and combination products) for Geisinger Health Plan members. It affects prescribers submitting new or renewal requests and those seeking exceptions to DHS-established quantity/dose limits.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyMigraine Acute Treatment Agents Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 5, 2026
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical documentation demonstrating diagnosis, prior therapies/trials or contraindications, and quantity/dose justification via PromptPA or fax.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleCovered agent classes
    prior authAuthorization requirement
    DHS limitsDHS limits exceptions
    specialist noted

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Specialist option

    Coverage Criteria for Acute Migraine Treatments

    Initial requests — class-specific prior trial/contraindication requirements

    Covered when the following class-specific conditions are met and documentation is submitted:

    Gepant acute use: For a GEPANT/small molecule CGRP inhibitor for the acute treatment of migraine (e.g., Nurtec ODT, Ubrelvy): tried and failed at least 2 triptans OR has a contraindication or an intolerance to triptans. For a non-preferred gepant: tried and failed or has a contraindication or an intolerance to the preferred gepants.

    Supported by form checkboxes

    Ditan (Reyvow): For a DITAN/5HT1 receptor agonist: tried and failed or has a contraindication or intolerance to the preferred triptans. For a non-preferred ditan: tried and failed or has a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents.
    Ergot alkaloid: For an ERGOT ALKALOID (e.g., Cafergot, D.H.E., Migranal): tried and failed or has a contraindication or intolerance to the following abortive drugs: caffeine/analgesic combination (e.g., Excedrin), NSAIDs, triptans, or a combination of an NSAID with a triptan. For a non-preferred ergot alkaloid: tried and failed or has a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents.

    Form lists examples (Cafergot, D.H.E., Migranal)

    Non-preferred triptan: For a NON-PREFERRED TRIPTAN: tried and failed or has a contraindication or an intolerance to the preferred triptans.
    Non-preferred NSAID: For a NON-PREFERRED NSAID (e.g., Elyxyb, diclofenac powder packet): tried and failed or has a contraindication or an intolerance to the preferred oral NSAIDs in the NSAIDs PDL class.

    Examples include Elyxyb, diclofenac powder packet

    Triptan-NSAID combination (e.g., Symbravo): For a NON-PREFERRED TRIPTAN-NSAID COMBINATION PRODUCT (e.g., sumatriptan-naproxen, Symbravo): tried and failed or has a contraindication or an intolerance to the preferred triptans AND has a clinical reason why the individual active ingredients cannot be used concurrently. For Symbravo specifically: tried and failed or has a contraindication or an intolerance to sumatriptan-naproxen tablet.
    Other non-preferred migraine agents: For ALL OTHER non-preferred Migraine Acute Treatment Agents: tried and failed or has a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents.

    Renewal requests

    Covered upon renewal when the following are met:

    General renewal improvement: Member experienced improvement in headache pain, symptoms, or duration.

    Required checkbox on renewal section

    Non-preferred triptan renewal: Tried and failed or has a contraindication or an intolerance to the preferred triptans.
    Gepant renewal: Tried and failed or has a contraindication or an intolerance to the preferred gepants.
    Non-preferred NSAID renewal: Tried and failed or has a contraindication or an intolerance to the preferred oral NSAIDs in the NSAIDs PDL class.
    Triptan-NSAID combination renewal:

    Quantity limits / Daily dose limits exceptions

    Requests exceeding DHS quantity/daily dose limits are covered only when documentation meets all of the following:

    Exceeding DHS limits: Requested medication is prescribed by a neurologist or a specialist certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS) OR the requested quantity/dose/frequency is supported by current medical compendia and/or peer-reviewed medical literature. Submit supporting documentation.

    Form asks prescriber specialty and asks for supporting references

    Adjunctive preventive therapy: For acute treatment, documentation must show evaluation for overuse of abortive headache medications AND one of the following: member will use the requested medication with at least one preventive medication (anticonvulsant, antidepressant, beta blocker, or CGRP monoclonal antibody) OR member tried and failed preventive medications OR member has intolerance/contraindication to preventive medications. Submit documentation specifying agents tried or reason for intolerance/contraindication.

    Multiple checkboxes provided for preventive therapy options

    Requests that do not include documentation supporting an exception to DHS quantity or daily dose limits or that fail to demonstrate specialist support or literature justification are not eligible for an exception. The form requires submission of documentation showing either that the medication was prescribed by a neurologist or a UCNS‑certified headache specialist, or that the requested quantity/dose/frequency is supported by current medical compendia or peer‑reviewed literature; if neither is provided, the request may be denied. For quantity/dose exception requests related to acute migraine treatment, the form additionally requires documentation of evaluation for medication overuse and evidence regarding preventive therapy or attempts at preventive agents as applicable.

    DHS Quantity and Dose Limits

    DHS quantity/daily dose limits
    Authority for limitsDHS-established quantity limits/daily dose limits apply; refer to the DHS website for applicable limits (https://www.pa.gov/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits).
    Prior authorization requiredAll requests that exceed DHS quantity limits/daily dose limits require prior authorization.
    Documentation requiredIf exceeding limits, submit documentation that the requested quantity/dose/frequency is supported by current medical compendia or peer‑reviewed literature.
    Specialist prescriberForm asks whether the prescriber is a neurologist or UCNS‑certified headache specialist; specialty status can support exceptions.
    Form instructionComplete the QUANTITY LIMITS/DAILY DOSE LIMITS section on the prior authorization form when the requested prescription exceeds DHS limits.

    Provider Requirements and Submission Instructions

    Prior Authorization

    Prior authorization required for acute migraine agents and DHS limit exceptions

    Prior authorization is required for all new and renewal requests for migraine acute treatment agents and for any request that exceeds DHS quantity/daily dose limits; complete the appropriate INITIAL or RENEWAL section and provide required supporting documentation.

    • Complete INITIAL or RENEWAL section on the form.
    • If request exceeds DHS limits, also complete the QUANTITY LIMITS/DAILY DOSE LIMITS section and provide supporting documentation.
    Step Therapy

    Document required step therapy / preferred-agent trials by drug class

    Document prior trials, intolerances, or contraindications to preferred agents as required by drug class: e.g., gepants require trial and failure of at least 2 triptans (or documented contraindication/intolerance); non-preferred agents require failure/intolerance/contraindication to preferred agents as listed on the form.

    • Gepants: Tried and failed ≥2 triptans or has contraindication/intolerance; non-preferred gepants require failure/intolerance/contraindication to preferred gepants.

    Background

    This prior authorization form applies to acute migraine pharmacologic options including gepants (small‑molecule CGRP inhibitors), ditans (5‑HT1 receptor agonists), triptans, ergot alkaloids, oral NSAIDs, and combination products (e.g., triptan‑NSAID combinations). Coverage and renewal criteria in the form set class‑specific requirements such as prior trials of preferred agents, documented contraindications or intolerances, and documentation required when requesting quantities or doses that exceed DHS limits.

    Key Definitions

    Gepant / small molecule CGRP inhibitor — definition and coverage note
    DefinitionGepant / small molecule CGRP inhibitor — acute migraine agents (e.g., rimegepant [Nurtec ODT], ubrogepant [Ubrelvy]).
    Initial coverage requirementTried and failed at least 2 triptans OR has a contraindication or intolerance to triptans; submit documentation.
    Non‑preferred gepantFor a non‑preferred gepant, tried and failed or has a contraindication or intolerance to the preferred gepants; document attempts or contraindications.
    Ditan / 5HT1 receptor agonist — definition and coverage note
    DefinitionDitan / 5HT1 receptor agonist — acute migraine agent (e.g., lasmiditan [Reyvow]).
    Initial coverage requirementTried and failed or has a contraindication or intolerance to the preferred triptans; submit documentation.
    Policy Summary
    PayerGeisinger Health Plan
    PolicyMigraine Acute Treatment Agents Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 5, 2026
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical documentation demonstrating diagnosis, prior therapies/trials or contraindications, and quantity/dose justification via PromptPA or fax.
    SourceLink
    On This Page
    Coverage Criteria for Acute Migraine TreatmentsDHS Quantity and Dose LimitsProvider Requirements and Submission InstructionsBackgroundKey Definitions
    Tried and failed or has a contraindication or an intolerance to the preferred triptans AND has a clinical reason why the individual active ingredients of the requested drug cannot be used concurrently. For Symbravo, tried and failed or has a contraindication or an intolerance to sumatriptan-naproxen tablet.
    Other non-preferred renewal: Tried and failed or has a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents.
  1. Ditans: Tried and failed or has contraindication/intolerance to preferred triptans; non-preferred ditans require failure/intolerance/contraindication to preferred migraine acute agents.
  2. Non-preferred triptans/NSAIDs/ergot alkaloids/combination products: Document required prior failures or clinical reasons per the form.
  3. Documentation Required

    Submit completed PA form with supporting clinical documentation

    Submit the completed Migraine Acute Treatment Agents Prior Authorization Form with all required clinical documentation demonstrating diagnosis, prior therapies/trials or contraindications/intolerances, quantity/dose justification, and any specialist certification; send via PromptPA or fax to Geisinger Health Plan.

    • Include diagnosis and DX code as requested on the form.
    • Attach documentation of prior trials/intolerances/contraindications and supporting literature when exceeding DHS limits.
    • Submit via PromptPA (https://ghp.promptpa.com) or fax to 570-271-5610.
    Billing Rule

    Authorization required when exceeding DHS quantity/daily dose limits

    All requests that exceed DHS-established quantity limits/daily dose limits require prior authorization and must include documentation that the requested quantity/dose/frequency is supported by current medical compendia or peer‑reviewed literature or that the medication is prescribed by a neurologist or UCNS‑certified headache specialist.

    • If exceeding DHS limits, indicate whether prescriber is neurologist or UCNS‑certified headache specialist on the form.
    • Provide supporting references from medical compendia or peer‑reviewed literature to justify requested quantity/dose/frequency.
    Denial Risk

    Denial risk if required trials, contraindications, or DHS-justifying documentation are not provided

    Requests for non-preferred agents or agents subject to step therapy will be denied if the form does not document required prior trials, contraindications, or intolerances; similarly, requests exceeding DHS limits risk denial if supporting specialist certification or literature is not provided.

    • Missing documentation of required prior failures/intolerances/contraindications to preferred agents may lead to denial.
    • Failure to provide specialist certification or medical literature to justify quantity/dose when exceeding DHS limits may lead to denial.
    Non‑preferred ditanFor a non‑preferred ditan, tried and failed or has a contraindication or intolerance to the preferred Migraine Acute Treatment Agents; document attempts or contraindications.